BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
6/8 — Strong
Priority Review
OPDUALAG (nivolumab and relatlimab-rmbw) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2022.
Drug data last refreshed 4h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDUALAG is a fixed-dose combination of nivolumab (a PD-1 inhibitor) and relatlimab (a LAG-3 inhibitor) administered intravenously. It is indicated for the treatment of melanoma and other solid tumors by blocking dual immune checkpoints to enhance anti-tumor T-cell responses. This combination approach targets both PD-1 and LAG-3 pathways to overcome resistance mechanisms in checkpoint inhibitor monotherapy.
$0.004BPart D
PeakEarly-stage peak-cycle product with modest Part D penetration (~$4M annually) indicates emerging adoption and opportunity for commercial team growth and market expansion initiatives.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Started Jun 2026
15 enrolled
Metastatic MelanomaLiver Metastases
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Started Nov 2025
20 enrolled
Locally Advanced Melanoma
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Started Aug 2025
30 enrolled
Basal Cell Carcinoma
Why This Matters for Your Career
Worked on OPDUALAG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.